We are in a time where healthcare information is readily available. How can patients keep up with new information? Dr George shares his perspective ⬇️
Bayer | Oncology
Pharmaceutical Manufacturing
At Bayer, we’re committed to a patient-centered approach to cancer care & are focused on innovation & change in oncology
About us
Over the last 20 years, the cancer treatment landscape has seen significant progress. However, there is still much work to be done to help the those living with cancer across the globe. With recent innovations in difficult-to-treat tumors, Bayer is at the forefront of the evolving global oncology landscape. At Bayer, we’re committed to a patient-centered approach to cancer care and are continuously working to bring about innovation and change in oncology. This channel is dedicated exclusively to oncology and all those impacted by the disease. We invite you to join us on this journey.
- Website
-
https://www.oncology.bayer.com/
External link for Bayer | Oncology
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
It is critical to include diverse patient populations in clinical trials evaluating novel treatments for prostate cancer. Hear from Dr. Isaac O. Asiedu👇
-
Everybody should have access to cancer care, no matter how remote their community may be. Hear from Dr. Isaac O. Asiedu 🔈
-
Sometimes, medical terminology can make patients feel like physicians are speaking a foreign language. How can this be improved? Hear from Dr Elena Castro 🎧
-
According to Prof. Dr. Axel S. Merseburger, AI is not the future of prostate cancer treatment – it’s the present. Want to know why? Listen below 🔈
-
What are the significant barriers to using AI in prostate cancer clinical practice? Prof. Dr. Axel S. Merseburger points to data protection. Listen below 👇
-
Bayer Oncology presented the latest data in precision medicine at #SNO2024 An updated analysis of the long-term efficacy and safety of a TRK inhibitor in patients with TRK fusion primary CNS tumors is available now 👉 https://lnkd.in/diWfPuKJ Abstract: CTNI-07, Oral Presentation
-
-
Bayer Oncology presented long-term follow-up data from adult patients with TRK fusion sarcomas treated with a TRK inhibitor 🩺 Explore the latest efficacy and safety data at #CTOS2024! https://lnkd.in/g2huqnXj Poster Presentation
-
-
NTRK gene fusions are oncogenic drivers in multiple tumor types, including sarcoma. Learn more about a TRK inhibitor as first-line treatment in patients with TRK fusion sarcomas at #CTOS2024: https://lnkd.in/g2huqnXj Poster Presentation #TRKFusionCancer
-